Retinal gene therapy company Nightstar scores $45 mln Series C


London-based Nightstar, a retinal gene therapy company, has closed $45 million in Series C financing. The backers were Wellington Management Company, Redmile Group, Syncona and New Enterprise Associates.

Source: Press Release

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!